C
rohn's disease (CD) is a chronic inflammatory disorder with a relapsing-remitting course, 1 that exhibits a heterogeneous disease spectrum. Although some patients experience a relatively quiescent course, others have frequent flares and severe ongoing subclinical inflammation. Continued luminal inflammatory activity leads to the development of stricturing and/or penetrating complications, in turn contributing to increased need for aggressive therapies, including anti-tumor necrosis factor (TNF) agents, surgeries, hospitalizations, and other health care utilization. 1, 2 Lémann Index (LI) quantifies the digestive tract damage mediated by CD over time. 3, 4 Calculation of the index involves grading of each segment of the gastrointestinal tract (with grades and segments being predefined) on 3 parameters (presence of stricturing or penetrating complications and surgical resection), while using data obtained from cross-sectional and endoscopic imaging. 3, 4 Change in LI or Delta LI (DLI) is an effective means of stratifying patients into distinct, clinically meaningful, CD phenotypes. 5, 6 We previously demonstrated that patients with aggressive disease phenotypes, as reflected by rapidly increasing LI, had higher disease activity and greater health care utilization during the interim across which DLI was tracked. 5 Financial burden from CD care is substantial and amounts to nearly $25,282-$26,192 annually (per patient) in the United States. 7 Health care expenditure in CD is largely dependent on the need for surgical intervention, expensive biological therapies, and hospitalization. [8] [9] [10] [11] [12] Because of variable disease course, financial burden is also not uniform across patients with CD, and previous studies have shown that the highest 2% of the patients disproportionately account for 34% of the total costs. 11 Delineating these Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.ibdjournal.org).
high utilizers of the health care system is essential in identifying more aggressive disease patterns which may warrant a change in our therapeutic algorithm, as well as to help in intensifying other cost reduction strategies in this patient subset. 13 In previous studies, poor socioeconomic status and the presence of comorbid medical and psychiatric conditions have been identified as risk factors for high utilization in patients with inflammatory bowel disease (IBD). [14] [15] [16] In our previous study, additional factors such as black race, use of opiates, penetrating CD phenotype, and the use of more aggressive medical therapy at first visit were baseline characteristics that showed association with increased health care utilization and expenditure over the next 5 years. 17 Given the ability of change in LI to delineate distinct CD phenotypes, we aimed to characterize the financial burden from all medical care in a 5-year prospective cohort of patients with CD stratified into LI-based disease phenotypes and to evaluate its utility in identifying the subset of the costliest patients.
MATERIALS AND METHODS

Study Population
This was an observational study conducted using a prospectively maintained, longitudinal natural history registry of consented patients with IBD, that is housed at the University of Pittsburgh Medical Center, which is a tertiary adult digestive disease center. Patients with a definitive CD diagnosis and with regular follow-up (defined as having at least one IBD clinic visit in each year) between January 1, 2009 and December 31, 2013 were identified. Patients with CD of less than 3 months duration were excluded. Charge data for the included patients were obtained for all health care services (i.e., not limited to gastrointestinal care) at the UPMC system (which includes .20 hospitals and . 500 outpatient sites) for the years 2009 to 2013. Patients with charge data missing for more than one consecutive year were excluded. Method of calculation of LI 4 and inclusion as well as exclusion criteria imposed on patients during calculation of LI for such a cohort has been described in detail in our previous studies. 5, 6 Briefly, patients who had undergone 2 or more CDrelated diagnostic imaging (endoscopic or radiologic) tests at least 3 years apart during the period of follow-up were included. Those who had undergone CD-related surgery during the study period without CD-related diagnostic imaging tests both preceding and following the surgery were excluded. Diagnostic tests' reports were reviewed and used to calculate LI with a Microsoft Excel-based calculator. An example of LI calculation is presented in Table 1 , Supplemental Digital Content 1, http://links. lww.com/IBD/B398. Finally, patients with LI calculated at 2 time points (distinguished as LI1 and LI2), and with complete financial health care data for the period of interest formed the study cohort. The study was approved by University of Pittsburgh Institutional Review Board (PRO14050636) and confidentiality was maintained for all study material.
Demographics, Clinical Data, and Delta LI
Patient demographics, disease characteristics, including Montreal classification at diagnosis, 18 health care utilization, treatment-related details (including steroids, immunomodulators, anti-TNF agents, opiates, and antidepressants) during the study and surgical history were extracted from the registry with manual confirmation using the electronic medical record. We chose to focus mainly on the medications used for direct management of CD, which are steroids, immunomodulators, and anti-TNF agents, as well as medications that are commonly used for symptom management in these patients; namely narcotic analgesics and antidepressants. Management of each patient's clinical data, including diagnostic testing and prescription of medications was performed based on their provider's discretion. Change in LI (LI2-LI1) was designated as Delta LI (DLI) and was used to stratify patients into 3 distinct categories of disease evolution: improvement (DLI ,0), no change (DLI ¼ 0), or deterioration (DLI .0). Disease activity was gauged prospectively at each clinical visit using metrics such as Harvey Bradshaw Index 19 and inflammatory biomarkers such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Elevation in ESR and CRP was defined as values greater than 20 mm/h and 0.8 mg/dL respectively, according to our institutional laboratory's upper limit of normal. Biomarkers and medications were charted on a range from 1 to 5, based on number of years with one or more abnormal values, or one or more prescriptions respectively. Health-related quality of life was gauged prospectively using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ). 20 
Financial Charge Data
Charge data were made available by the Center for Assistance in Research using the electronic medical record, which is an information technology support group at UPMC. Because charges are institutionally specific, they provide a good framework for spending patterns, whereas costs reflect a payer or societal perspective. 21 Hence, we chose to focus on the former. Total financial charges were broken down as professional service, inpatient care, and outpatient medication (immunomodulator and anti-TNF agent) charges. The choice of approximating only these medications is due to their relatively dominant contribution to medication expenses. Professional service charges comprised physician or specialized personnel fees for outpatient clinic visits and testing (laboratory, radiology, endoscopy, pathology, and other diagnostic tests such as echocardiogram, mammogram, pulmonary function tests etc), emergency department (ED) testing and physician services, and fees for outpatient surgery and anesthesia services. Inpatient charges included fees for boarding, administration, medication, diagnostic testing and procedural charges, and surgery incurred during hospitalization. Outpatient biological agent charges were imputed using average Medicare Part B Allowance Limit statistics (available at http://www.cms. gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/index.html) using conservative standard dosing guidelines (infliximab: 5 mg/kg every 8 weeks, adalimumab: 40 mg every 2 weeks, certolizumab: 400 mg every 4 weeks) to approximate mean annual biological cost. If a patient received a biological agent as an inpatient (typically as a single dose), this was accounted for in the total inpatient hospitalization charge using institution-specific charge rates. Outpatient pharmacy charges and total parenteral nutrition charges were not available for inclusion in our charge data as these were insurance payer derived rather than from the health care system. All charges were in US dollars and were inflated to 2013 base year using Consumer Price Index adjustment rates (http://www.bLI.gov/data/inflation_calculator.htm).
Statistical Analysis
Given the skewed distribution of financial charges and health care utilization, data distribution was deemed nonnormal by the Kolmogorov-Smirnov test. Categorical variables are expressed as percentages and continuous variables as median [interquartile range (IQR)]. Chi-squared analysis was used for contingency tables. Difference between groups was evaluated using Mann-Whitney U test and Kruskal-Wallis test for nonparametric continuous data. Because the total financial charges violated normality, it was log transformed and then used as the dependent variable for univariate analysis that assessed its correlation with demographic and disease characteristics including disease parameters as per Montreal classification, 18 activity metrics, inflammatory markers, LI scores, and DLI. Given that surgery, health care visits, hospitalizations, and medications during the study period would strongly influence financial charges, these variables were not included in the regression analysis. Covariates demonstrating P , 0.1 in univariate analysis were included in the multivariate linear regression analysis. The 19.1 SPSS statistical software (SPSS, Chicago, USA) was used to perform all analyses. P values ,0.05 were considered statistically significant. All tests were 2-sided.
RESULTS
Study Population
In the IBD registry, 430 patients with a definite diagnosis of CD and with regular follow-up between 2009 and 2013 were identified. Among them, 363 patients had LI calculated at 2 time points, 6 months apart during the study period. Complete financial charge data were available for 243 of them and these patients formed the study population. The study cohort comprised 58% women, median age of 44 years (IQR: 34-56) and median disease duration of 12 years (IQR: 7-19) ( Table 1) . Nearly 72% (175/243) of our patients had undergone at least one CD-related surgical procedure before study inclusion and 102 (42%) patients required CD-related surgery during the study period. Psychiatric comorbidities were concomitantly present in 32% (78/243) of the study population.
For the entire cohort, the median LI1 was 8.3 (IQR: 1.3-12.3), median LI2 was 8.9 (IQR: 2.5-20.6), and the median DLI was 0.4 (IQR: 0-3.8) ( Table 1 ). The median interval between LI1 and LI2 was 48 months (IQR: 42-55). Regarding changes in DLI, majority of the patients in the cohort showed worsening gut destruction (53.5%) during the 5 years, which was mostly secondary to surgical resection, followed by development of ileal strictures or perianal fistulas, whereas 30.9% showed stable disease and 15.6% experienced improvement in bowel damage (Table 2) .
Subgroup Analysis
There was no significant difference regarding sex, age, body mass index, smoking status, or age at diagnosis across the DLI trajectories (Table 2) . Disease duration was longer in the stable damage group (P ¼ 0.029). Features of disease location, such as colonic involvement alone, showed significant differences across the groups (P ¼ 0.042). Nonstricturing nonpenetrating phenotype was less common among the worsening disease group (P ¼ 0.002). Worsening disease group was more likely to have stricturing disease (P ¼ 0.035) and perianal involvement (P ¼ 0.014). They also had significantly higher CD-related surgical exposure both before and during the study (for both comparisons, P , 0.001). This subset of patients suffered from psychiatric comorbidities more frequently as well (P ¼ 0.029). LI1 showed no significant variation across the groups (P ¼ 0.357); however, LI2 and DLI were significantly higher in the worsening disease phenotype (P , 0.001 for both parameters). The duration across which DLI was calculated was not different across the groups (P ¼ 0.095); however on individual comparison between the stable and worsening group, this duration was noted to be significantly higher in the latter (P ¼ 0.042). Further comparison of characteristics between the stable and worsening groups was performed after adjusting for this variation in interval between the 2 LI assessments. Detailed results of the comparison of individual groups are listed in Table 2 . CRP elevation showed significant variability (P , 0.001) with more frequent elevations noted in patients in the worsening group, and the variation in elevation in ESR also showed a trend toward significance (P ¼ 0.057). Median 5-year Harvey Bradshaw Index scores were not different across the groups (P ¼ 0.299); however, patients in the worsening trajectory had significantly lower median 5-year SIBDQ scores (P ¼ 0.036). Patients with worsening trajectory had greater number of phone calls and visits to the IBD clinic (P , 0.001 for both) and the ED (P ¼ 0.002); however, comparison of hospitalizations showed no significant difference (P ¼ 0.104). The frequency of steroid (P ¼ 0.001), anti-TNF (P ¼ 0.009), and opioid (P ¼ 0.049) agent use was significantly higher in the worsening subset. However, use of immunomodulators (P ¼ 0.583) and antidepressants (P ¼ 0.586) did not show significant variation.
Financial Data
Healthcare charges for the 243 study patients between 2009 and 2013 totaled $56,523,835 with median charge of $116,838 (IQR: $45,643-$240,398) per patient. Expenditure patterns were markedly skewed with 53.5% of the cohort (patients with DLI .0) accounting for 77.5% of the total cost burden, and this trend was noted for all categories of charges (Table 3 and Fig. 1 ). Although the median 5-year charges were largely comparable at $73,698 and $68,244 for patients in the improving and stable groups (P ¼ 0.796), it was markedly higher at $187,579 in patients of the worsening group (P , 0.001 for comparison with each of the other trajectories). For the cohort, hospitalization and anti-TNF agent use accounted for 67% and 15.2% of the total charges, respectively. There was a trend of increase in proportion of charges accounted for by hospitalizations across the 3 trajectories (improving versus stable versus worsening: 45.4% versus 51.7% versus 72%) and a corresponding decrease in the share of expenses attributed to anti-TNF therapy (improving versus stable versus worsening: 34.4% versus 22% versus 12%). Proportion of expenditure attributed to surgeries (both outpatient and inpatient) was delineated and was found to be 10% for the entire cohort and showed a trend for increase across the 3 groups (improving versus stable versus worsening: 4% versus 6.4% versus 10.7%) as seen in Figure 2 . Multivariate linear regression analysis showed independent significant positive correlation of log-transformed total 5-year health care expenditure with LI2 (coefficient ¼ 0.01, P ¼ 0.001) and DLI (coefficient ¼ 0.014, P ¼ 0.001), and negative correlation with age (coefficient ¼ 20.007, P ¼ 0.029) and 5-year SIBDQ (coefficient ¼ 20.007, P ¼ 0.024) ( Table 4) . Also logtransformed total 5-year surgical expenditure showed significant 
DISCUSSION
In this study, we found that CD exacted a significant medical financial burden over 5 years, which was largely secondary to hospitalizations and advanced medical therapies. CD patients with the aggressive LI phenotype showed significantly greater health care utilization and correspondingly incurred a disproportionately higher financial charge burden compared with the rest of the cohort. Health care expenditure is independently associated with DLI.
CD is a progressive inflammatory disease state and development of complications such as fibrostenotic stricture or penetrating lesions (fistula and abscess) of the bowel requiring surgical management is frequent. Nearly half of the patients with CD require surgery within 10 years from diagnosis, and the cumulative incidence of first, second, and third procedures is as high as 60%, 48%, and 54% at 20 years after diagnosis 22 ; thus amounting to significant healthcare burden. This is reflected in the financial burden from the disease, which in the United States has been estimated at $10.9 to 15.5 billion per year. 7 Given the heterogeneity in disease course and complications, the financial burden from CD is known to be skewed. Previous studies have suggested that the upper quartile of costs accounted for 80% of the total financial expenses. 10 In our previous, 5-year analysis of 1600 patients with IBD, 54.8% (n ¼ 876) of whom had CD, a subset of 9% of patients were found to account for 51.2% of the 5-year cumulative financial charges for the entire cohort. 17 With the rising cost of health care in the United States, there is now a mounting interest to identify these high utilizers so that interventions to improve coordination of care and preventive care for them may be tailored and better enforced. 23 Several studies have highlighted disease characteristics associated with high expenditures which have included the presence of comorbid medical and psychiatric conditions, higher disease activity scores and elevated inflammatory biomarkers, worse health-related quality of life scores, higher health care utilization, need for chronic steroid or immunosuppressive drug therapy, and surgical procedures. 9, 10, 17 Although these studies define conditions associated with high expenditures, it does not provide a means of delineating these high utilizing groups. This need for identifying the high utilizers with the aggressive disease course is also important in the realm of changing therapeutic strategies in CD. There is now a growing consensus that the focus in management of CD should shift from symptom and inflammation control to pre-emptively preventing organ damage and minimizing long-term sequelae to attempt to alter disease course. This would warrant the early use of expensive anti-TNF therapy, and LI trajectory could serve as a primary outcome tool in the assessment of efficacy of such novel therapeutic strategies.
Although there is still debate regarding the content validity, interrater reliability, ideal diagnostic modality for index calculation, and efficient and effective incorporation of LI into clinical practice, LI has been shown to reflect disease course and shows worsening with persistent clinical activity 24 and improvement with anti-TNF therapy. 25 Change in LI or DLI has been demonstrated to be a useful tool to chart CD trajectory and segregate heterogeneous disease phenotypes. 5, 6 Stratification of our study cohort based on DLI showed that more often patients showed worsening (53.5%) or stable bowel damage (30.9%), with a smaller fraction showing improvement in LI (15.6%). Also, a significant share of patients (42%) underwent CD-related surgery during the 5-year study period which could potentially be explained by 2 factors; first, given that this registry is housed at a tertiary level digestive disease center, our patient population is more often sicker than the usual general IBD population and second, since patients who undergo surgery are more likely to undergo multiple sets of diagnostic testing, their likelihood of inclusion in the study is increased.
Despite the shorter duration of CD in the worsening group, a significantly greater proportion of the patients showed a stricturing phenotype or had perianal involvement and had undergone CD-related surgery before the study period, thus suggestive of a more aggressive disease course. In addition, they also suffered from psychiatric comorbidities more frequently; which merit the closer attention of our therapeutic interventions because they stem from or result in an inability to cope and eventually influence health care utilization and expenditure. During the 5-year observation period, this aggressive disease group demonstrated significantly higher disease activity (more frequent elevation of CRP), greater health care utilization (more IBD clinic visits and phone calls and ED visits), greater need for aggressive medical therapies (steroid, anti-TNF agent use, and surgery), and worse quality of life (lower SIBDQ scores) compared with the rest of the cohort. Surprisingly, the variability in ESR elevation and Harvey Bradshaw Index scores was not significantly different across the groups and may reflect on the performance and limitations of these metrics as disease activity assessment tools in patients with CD; however, more studies with larger study populations would be required to investigate these patterns further. Interestingly, the use of steroids and anti-TNF agents was comparable in both the extreme phenotypes, suggestive of a similar inflammatory course in both trajectories, but with varied response to treatment.
On comparing the stable and worsening trajectory, it is noted that the patients in the former were older, more likely to have nonstricturing nonpenetrating disease behavior, longer disease duration, lower frequency of inflammatory biomarker elevation, less health care utilization (IBD clinic, ED visits, and hospitalizations), and need for steroids and anti-TNF agents; which provides further evidence for minimal underlying inflammatory activity and disease stability in this subset of patients.
The median annual health care expenditure per patient for our cohort was $23,368, which is comparable with previous population estimates of $25,282-$26,192 . However, on subgroup analysis, we noted that improving ($14,739.6) and stable ($13,648.84) disease groups had lower median charges, whereas the median for the worsening disease group was notably higher ($37,515.86). As expected, health care expenditure mirrored the pattern of utilization across each trajectory. Patients with bowel damage deterioration incurred disproportionately greater expenses on all fronts compared with the rest of the cohort. The only expense domain where the 3 groups were comparable was charges for immunomodulators, which is not surprising given that their use was similar in all groups. Although number of hospitalizations was not significantly different across the groups, inpatient charges were markedly higher in the worsening group because of greater frequency of inpatient diagnostic tests and procedures. Expenses for patients in improving and stable groups were largely comparable, except for surgical charges which were significantly higher in the latter (P ¼ 0.021) given that a greater fraction of these patients underwent CD-related surgery during the study (16.0% versus 10.6%). Results of the regression analysis suggest that higher total 5-year financial charges are associated with higher LI2 and DLI and lower 5-year SIBDQ scores.
This study has several strengths. First, the prospective monitoring of the cohort for 5 years allows for temporal variation in disease activity to assess longitudinal patterns of disease burden. Second, availability of in-depth analysis of disease characteristics and health care expenditure patterns allows correlation between disease activity and financial burden and identification of specific areas of utilization which may benefit from cost-reducing interventions. Third, the evaluation of total health care expenditure, rather than gastrointestinal care-related expenses alone gives a holistic perspective of the disease and its impact on various aspects of a patient's well-being, and may reveal noteworthy associations on further analysis in future studies.
Our study is not without limitations. First, total financial burden was restricted to health care services at our hospital system. As financial charges vary between institutions, the generalizability of our results may be limited. Also, we were unable to assess health care obtained at centers apart from our own, thus potentially under-accounting the utilization and charge patterns of the cohort. Second, several traits of the LI are still under debate, with some of them being-ideal diagnostic modality for index calculation, consistency across evaluators and time efficiency for calculation. The limitations that arise with calculating LI retrospectively have been elucidated in detail in our previous studies 5, 6 and would apply to the current study as well, which include shortcomings such as nonprotocolized diagnostic testing and use of variable combination of tests for index calculation, which might both affect precision of scores; hence, we chose to focus on the trend in index values over time rather than absolute values and this reflects a practical incorporation of this tool and a real-world analysis of the disease course in these patients. Third, baseline characteristics of the study cohort showed highly variable disease duration and phenotypes, which are well known to influence the likelihood of development of complications, thus potentially impacting LI 1,2,26 as well as health care utilization, and hence we only chose to focus on change in damage and its association with health status during the study period.
In conclusion, care of patients with CD constitutes a significant medical financial burden with a subpopulation of patients accounting for disproportionately high expenditure. Delta LI is a useful tool for distinguishing clinically distinct and meaningful CD phenotypes. We demonstrate that it is also useful to reveal and characterize the disparity in health care expenses in these patients. Further research should focus on patients in the worsening LI trajectories who suffer the most aggressive disease patterns and represent the highest utilizers of the health care system. 
